"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00774787","Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses",,"Completed","Has Results","Actinic Keratoses","Drug: imiquimod 5% cream","Change From Baseline in Actinic Keratoses Count at 4-8 Weeks Post-treatment|Cosmetic Appearance Score at 4-8 Weeks Post-treatment","Rigel Dermatology","All","18 Years and older   (Adult, Older Adult)","Phase 4","27","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","08US02IMIQ-Rigel","October 2008","March 2010","March 2010","October 17, 2008","October 27, 2010","November 6, 2016","Spencer Dermatology and Skin Surgery, Saint Petersburg, Florida, United States|James Del Rosso, Henderson, Nevada, United States|Rigel Dermatology, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00774787"
2,"NCT00805467","Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies",,"Terminated","Has Results","Rheumatoid Arthritis","Drug: Fostamatinib Disodium (R935788)","Percentage of Patients Who Had at Least 1 Treatment Emergent Adverse Event in Any Category|DAS28-CRP Score|HAQ-DI Score","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","624","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-935788-012|D4300C00021","August 2008","August 2013","August 2013","December 9, 2008","June 25, 2014","June 25, 2014","Research Site, La Jolla, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Maria, California, United States|Research Site, Hamden, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Aventura, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur D'Alene, Idaho, United States|Research Site, South Bend, Indiana, United States|Research Site, Elizabethtown, Kentucky, United States|Research Site, Cumberland, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Lansing, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Roslyn, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Mayfiled Village, Ohio, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Oklahoma City, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Antwerp, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Medellín, Colombia|Research Site, Bordeaux, France|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Würzburg, Germany|Research Site, Siena, Italy|Research Site, Udine, Italy|Research Site, Chihuahua, Mexico|Research Site, Cuernava, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Guadalajara, Mexico|Research Site, Leon, Mexico|Research Site, Mexcio, Mexico|Research Site, Mexico, Mexico|Research Site, Morelia, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Jesus Maria, Peru|Research Site, Lima, Peru|Research Site, Białystok, Poland|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Toruń, Poland|Research Site, Wroclaw, Poland|Research Site, Zyrardów, Poland|Research Site, Brailari, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Sf. Gheorghe, Romania|Research Site, Sibiu, Romania",,"https://ClinicalTrials.gov/show/NCT00805467"
3,"NCT04304300","Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes","RIGEL","Recruiting","No Results Available","Astrocytoma, Grade II|Astrocytoma, Grade III|Oligodendroglioma|Oligodendroglioma, Anaplastic",,"Toxicity (selected CTCAE 5.0 items)|Neurocognitive testing|Next intervention free survival (NIFS)|Progression Free Survival (PFS)|Overall Survival (OS)|Health Related Quality of Life (HRQOL)|Health - Related Economics","Erasmus Medical Center|HollandPTC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Leiden University Medical Center|Delft University of Technology|Medical Center Haaglanden","All","18 Years and older   (Adult, Older Adult)",,"79","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL69780.078.19|Netherlands Trial Register","December 10, 2019","May 2024","May 2026","March 11, 2020",,"March 25, 2020","Erasmus MC, Rotterdam, Zuid Holland, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|HollandPTC, Delft, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Haaglanden Medical Center, Leidschendam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04304300"
4,"NCT02612558","A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)","SOAR","Completed","No Results Available","Warm Antibody Autoimmune Hemolytic Anemia","Drug: Fostamatinib 150 mg bid","Hemoglobin response","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-935788-053","July 2016","December 2019","December 2019","November 24, 2015",,"July 21, 2021","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC, Tucson, Arizona, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|LAC/USC Health Center, Los Angeles, California, United States|University of California at San Francisco, San Francisco, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Mid-Florida Hematology & Oncology Centers, P.A., Orange City, Florida, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Rcca Md Llc, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MidMichigan Health Cancer Center, Midland, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|W.G. ""Bill"" Hefner VA Medical Center, Salisbury, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Promedica Flower Hospital, Sylvania, Ohio, United States|M. Francisco Gonzalez, M.D., P.A., Sumter, South Carolina, United States|Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States|Clear Lake Specialties, Webster, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|Hamilton Health Sciences- McMaster University Medical Centre, Hamilton, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02612558"
5,"NCT02433236","Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy",,"Withdrawn","No Results Available","IGA Nephropathy","Drug: Fostamatinib Disodium tablet 100 mg|Drug: Fostamatinib Disodium tablet 150 mg","Number of Participants with mean change of Proteinuria as measured by spot urine protein/creatinine ratio (sPCR)","Rigel Pharmaceuticals","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-935788-051","September 2015","September 2015",,"May 4, 2015",,"October 23, 2015",,,"https://ClinicalTrials.gov/show/NCT02433236"
6,"NCT02112838","Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy",,"Completed","Has Results","IGA Nephropathy","Drug: Fostamatinib 150 mg|Drug: Fostamatinib 100 mg|Drug: Placebo","Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24|Mean Change From Pre-treatment to Post-treatment in Mesangial Hypercellularity (M) on Renal Biopsies.|Percentage of Subjects With ≥50% Reduction in sPCR From Baseline (Visit 2) at Week 24 (Visit 9).|Percentage of Subjects With ≥ 30% Reduction in Proteinuria From Baseline (Visit 2) at 24 Weeks (Visit 9).|Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Endocapillary Hypercellularity (E) on Renal Biopsies.|Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Segmental Sclerosis/Adhesion (S) on Renal Biopsies.|Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Global Glomerulosclerosis Score on Renal Biopsies.|Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Tubulointerstitial Scarring (T) on Renal Biopsies.|Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Cellular/Fibrocellular Crescent Score on Renal Biopsies.|Mean Change From Baseline (Visit 2) of eGFR at 12 Weeks (Visit 7).|Mean Change From Baseline (Visit 2) of eGFR at 24 Weeks (Visit 9).|Mean Change From Baseline (Visit 2) of Proteinuria at 12 Weeks (Visit 7).|Percentage of Subjects With sPCR <50 mg/mmol (500 mg/g) at 12 Weeks (Visit 7).|Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 12 Weeks (Visit 7).|Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 24 Weeks (Visit 9).","Rigel Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-050|2014-000331-16","October 2014","March 23, 2018","November 12, 2018","April 14, 2014","June 27, 2019","June 27, 2019","Stanford University Medical, Palo Alto, California, United States|Nephrology Associates PC, University Hospital, Professional Center 1, Augusta, Georgia, United States|Ohio State University, Columbus, Ohio, United States|Southeast Renal Research Institute, Chattanooga, Tennessee, United States|Medical University of Graz, Graz, Steiermark, Austria|Medical University Vienna, Nephrology, Vienna, Austria|Medical University of Heidelberg, Heidelberg, Baden-Wurtemberberg, Germany|Klinikum der Universität München, Munich, Bayern, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Sachsen, Germany|Medical University of Jena, Jena, Thueringen, Germany|Prince of Wales Hospital, Hong Kong, Sha Tin, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|China Medical University Hospital, Taichung, Taiwan|School of Medicine, Chang Gung University, Chang Gung Memorial Hospital, Taoyuan, Taiwan|Addenbrookes Hospital, Cambridge, United Kingdom|Cardiff University, Cardiff, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Royal Free Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02112838/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02112838/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02112838"
7,"NCT02077192","Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)",,"Completed","No Results Available","Immune Thrombocytopenic Purpura","Drug: Fostamatinib Disodium","Number of Participants with platelet count of at least 50,000/µL as a Measure of Safety and Efficacy","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","124","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-935788-049|2013-005454-30","July 2014","June 1, 2020","June 1, 2020","March 4, 2014",,"May 25, 2021","Arizona Oncology Associates, Tucson, Arizona, United States|Bleeding & Clotting Disorders Institute, Peoria, Illinois, United States|Horizon Oncology Research, Inc, Lafayette, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|East Carolina University, Brody School of Medicine, Greenville, North Carolina, United States|W.G. ""Bill"" Hefner VA Medical Center, Salisbury, North Carolina, United States|Signal Point Clinical Research Center LLC, Middletown, Ohio, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|The Alfred, Melbourne, Victoria, Australia|Perth Blood Institute, Nedlands, Western Australia, Australia|Hanusch-Krankenhaus Wiener Gebietskrankenkasse, Vienna, Austria|Specialized Hospital for Active Treatment of Hematology Diseases, EAD, Sofia, Department of Chemotherapy, Hemotherapy and Blood Inherited Diseases to Clinic of Clinical Hematology;, Sofia, BG, Bulgaria|UMHAT Dr. Georgi Stranski, EAD, Pleven, Clinic of Hematology, Pleven, Bulgaria|UMHAT Aleksandrovska, EAD, Sofia, Bulgaria|MHAT Hristo Botev, AD, Vratsa, First Internal Department, Vratsa, Bulgaria|Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, Czechia|Herlev Hospital, Herlev, DK, Denmark|Pecsi Tudomanyegyetem Klinikai Kozpont, I. sz. Belgyogyaszati Klinika, Pecs, Hungary|Istituto di Ematologia ""Lorenzo e Ariosto Seràgnoli"", Bologna, BO, Italy|Azienda Ospedaliero-Universitaria ""Santa Maria della Misericordia"" - Clinica Ematologica, Udine, Italy|HAGA ziekenhuis, Den Haag, NL, Netherlands|Haukeland universitetssykehus, Helse Bergen HF, Bergen, Norway|Sykehuset Østfold Kalnes, Grålum, Norway|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocrlaw, Wroclaw, Dolnoslaski, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka, Slupsk, PO, Poland|Lkinika Hematologii I Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|SPZOZ Szpital Uniwersytecki w Krakowie Pracownia Separacji Krwinek i Bank Komórek Krwiotwórczych Klinika Hematologii, Kraków, Poland|Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Łodzi, Lodz, Poland|Specjalistyczny Gabinet Lekarski, Lublin, Poland|Szpital Wojewodzki w Opolu, Opole, Poland|Instytut Hematologii I Transfuzjologii, Warszawa, Poland|Spitalul Clinic Colentina, Hematologie, Bucuresti, Romania|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitari i Politécnic La Fe de Valencia, Valencia, Spain|Colchester General Hospital, Colchester, Essex, United Kingdom|Royal Victoria Infirmary, Newcastle-upon-Tyne, UK, United Kingdom|Kent & Canterbury Hospital, Canterbury, United Kingdom|James Paget University Hospital, Great Yarmouth, United Kingdom|St. James's Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|University College Hospital, London, United Kingdom|Cancer and Haematology Centre, Oxford, United Kingdom|University Hospital of North Midlands NHS Trust, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02077192"
8,"NCT02076412","A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","FIT","Completed","Has Results","Immune Thrombocytopenic Purpura","Drug: Fostamatinib Disodium|Drug: Placebo","Number of Participants With Stable Platelet Response of at Least 50,000/µL|Number of Participants With Platelet Count ≥ 50,000/µL at Week 12|Number of Participants With Platelet Count ≥ 50,000/µL at Week 24|Number of Participants With Platelet Count ≥ 30,000/μL and at Least 20,000/μL Above Baseline at Week 12|Number of Participants With Platelet Count ≥ 30,000/μL and at Least 20,000/μL Above Baseline at Week 24|Frequency and Severity of Bleeding According to the ITP Bleeding Score (IBLS)|Frequency and Severity of Bleeding According to the World Health Organization (WHO) Bleeding Scale","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-048|2013-005453-76","January 2015","August 2016","August 2016","March 3, 2014","January 25, 2019","January 25, 2019","Hematology Oncology Associates of Rockland Division of Highland Medical PC, Nyack, New York, United States|Hanusch-Krankenhaus Wiener Gebietskrankenkasse, Vienna, AU, Austria|Medizinische Universitaet Wien / AKH Wien, Wien, AU, Austria|LKH Feldkirch at LKH Rankweil, Rankweil, Austria|Specialized Hospital for Active Treatment of Hematology Diseases, EAD, Sofia, Department of Chemotherapy, Hemotherapy and Blood Inherited Diseases to Clinic of Clinical Hematology;, Sofia, BG, Bulgaria|MHAT Hristo Botev, AD, Vratsa, First Internal Department, Vratsa, BG, Bulgaria|UMHAT Dr. Georgi Stranski, EAD, Pleven, Clinic of Hematology, Pleven, Bulgaria|UMHAT Aleksandrovska, EAD, Clinic of Clinical Hematology, Sofia, Bulgaria|Fakultni nemocnice Brno, Brno, CZ, Czechia|Hospital Kyjov, Kyjov, CZ, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice, Linterní Klinika, Klinika hematologie, Praha 2, Czechia|Universitaetsklinikum Giessen und Marburg (UKGM), Giessen, DE, Germany|Werlhof Institut GmbH, Hannover, DE, Germany|Charit Berlin - Campus Benjamin Franklin, Berlin, Germany|Marien Hospital Duesseldorf, Duesseldorf, Germany|Universittsklinikum Essen, Essen, Germany|Haukeland University Hospital, Bergen, Norway|Sykehuset Østfold Fredrikstad, Fredrikstad, Norway|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpital Uniwersytecki, Krakow, Poland|Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Łodzi, Lodz, Poland|Specjalistyczny Gabinet Lekarski, Lublin, Poland|Szpital Wojewodzki w Opolu, Opole, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka, Slupsk, Poland|Instytut Hematologii I Transfuzjologii, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocrlaw, Wroclaw, Poland|Spitalul Clinic Judetean de Urgenta Tirgu-Mures, Sectia Medicina Interna 1, Compartiment Hematologie, Targu Mures, Mures, Romania|Spitalul Clinic Colentina, Hematologie, Bucuresti, Romania|Spitalul Clinic Coltea, Hematologie, Bucuresti, Romania|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Universitariola Paz, Madrid, Spain|Hospital Universitari i Politécnic La Fe de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02076412"
9,"NCT02076399","A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","FIT","Completed","Has Results","Immune Thrombocytopenic Purpura","Drug: Fostamatinib disodium|Drug: Placebo","Number of Participants With Stable Platelet Response (Count of ≥50,000/µL on at Least 4 of the Last 6 Scheduled Visits Between Weeks 14 and 24)|Number of Participants With Platelet Count ≥ 50,000/µL at Week 12|Number of Participants With Platelet Count ≥ 50,000/µL at Week 24|Platelet Count ≥ 30,000/μL and ≥ 20,000/μL Above Baseline in Subjects With Baseline Platelet Count of <15,000/μL at Week 12.|Platelet Count ≥ 30,000/μL and ≥ 20,000/μL Above Baseline in Subjects With Baseline Platelet Count of <15,000/μL at Week 24.|Mean of the ITP Bleeding Score (IBLS)|Mean of World Health Organization (WHO) Bleeding Scale","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-047|2013-005452-15","July 14, 2014","April 21, 2016","April 21, 2016","March 3, 2014","January 11, 2019","February 12, 2019","Arizona Oncology Associates, Tucson, Arizona, United States|University of Southern California, Los Angeles, California, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Bleeding & Clotting Disorders Institute, Peoria, Illinois, United States|Horizon Oncology Research, Inc, Lafayette, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|Pitt County Memorial Hospital, Greenville, North Carolina, United States|Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Signal Point Clinical Research Center LLC, Middletown, Ohio, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Frankston Hospital, Frankston, Victoria, Australia|Dept of Haematology, The Alfred Hospital and Monash Medical Centre, Melbourne, Victoria, Australia|Perth Blood Institute, Nedlands, Western Australia, Australia|Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Herlev Hospital University of Copenhagen, Department of Hematology L124, Herlev, DK, Denmark|Dept. of Haematology, Odense University Hospital, Odense C, DK, Denmark|Hematological department, Roskilde Hospital, Roskilde, DK, Denmark|Aarhus University Hospital, Aalborg, Denmark|Semmelweis University 1st, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Pecs University, Pecs, Hungary|Ematologia - Padigilione 8, Policinico S. Orsola Malpighi, Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy|Ospedale San Raffaele S.r.l. Dipartimento di Oncoematologia, Milano, Italy|Universitã Federico II di Napoli, Napoli, Italy|OspedaleCivile-ClinicaEmatologica/PUGD, Udine, Italy|ULSS 6 Vicenza-Ospedale San Bortolo di Vicenza, Vicenza, Italy|HAGA ziekenhuis, Haag, NL, Netherlands|Kent & Canterbury Hospital, Kent, Canterbury, United Kingdom|Colchester General Hospital, Colchester, Essex, United Kingdom|Royal Liverpool University Hospital, Liverpool, UK, United Kingdom|St. James's Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal London Hospital, London, United Kingdom|Hammersmith Hospital, Catherine Lewis Centre, London, United Kingdom|University College Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom|James Paget University Hospital, Norfolk, United Kingdom|Oxford University Hospital, Oxford, United Kingdom|University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02076399"
10,"NCT02040623","Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)","DROPS-2","Completed","Has Results","Chronic Graft-versus-host Disease","Drug: R348 Ophthalmic Solution, 0.2%|Drug: R348 Ophthalmic Solution, 0.5%|Other: Placebo Ophthalmic Solution","Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks.","Rigel Pharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-932348-004","March 2014","July 2016","July 2016","January 20, 2014","October 10, 2016","October 10, 2016","U. Miami - Bascom Palmer Eye Institute, Plantation, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02040623"
11,"NCT03668002","Trial of Fistula Versus Graft in Elderly Patients",,"Recruiting","No Results Available","End Stage Renal Disease|Arteriovenous Fistula|Arteriovenous Graft","Procedure: Arteriovenous Fistula (AVF)|Procedure: Arteriovenous Graft (AVG)","Proportion of subjects that received assigned AV access (AVF vs. AVG)|Rate of accrual of subjects to the study","University of Pittsburgh","All","65 Years and older   (Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO17100473","September 14, 2018","August 31, 2023","August 31, 2024","September 12, 2018",,"September 5, 2021","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03668002"
12,"NCT00326339","Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: R788|Drug: Placebo","The Primary Efficacy parameter is ACR20 response rate at 3 months post dosing.|ACR 20/50 responses over time|Disease Activity Score (DAS) at baseline and endpoint|Mean changes (SDs) from baseline in Swollen Joint Count (28 joint count)|Mean changes (SDs) from baseline in Tender Joint Count (28 joint count)|Mean changes (SDs) from baseline in Physician global assessment of disease activity by visual analog scale (VAS)|Mean changes (SDs) from baseline in Patient global assessment of disease activity by VAS|Mean changes (SDs) from baseline in Patient assessment of pain by VAS|Mean changes (SDs) from baseline in HAQ-DI|Mean changes (SDs) from baseline in CRP|The frequency and severity of Liver Function Test abnormalities, especially ALT and alkaline phosphatase|The frequency and severity of hematopoietic cytopenias, principally effects on neutrophil, erythrocyte, and lymphocyte counts|The frequency and severity of clinically significant adverse events, especially skin rash, postural dizziness, and alterations in blood pressure and other relevant clinical outcomes","Rigel Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-006","August 2006","October 2007","December 2007","May 16, 2006",,"April 20, 2009","Pacific Arthritis Center Medical Group, Santa Maria, California, United States|DMI research, Ocala, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Arthritis & Osteoporosis Treatment Center, Orange Park, Florida, United States|Arthritis Associates Inc., Orlando, Florida, United States|Arthritis Research of Florida, Inc., Palm Harbor, Florida, United States|Arthritis Research of Florida, Palm Harbor, Florida, United States|Lovelace Scientific Resources, Sarasota, Florida, United States|The Center for Arthritis and Rheumatic Diseas, South Miami, Florida, United States|Coeur d'Alene Arthritis Clinical Trials, Coeur d'Alene, Idaho, United States|The Arthritis Center, Springfield, Illinois, United States|MMG Clinical Research, South Bend, Indiana, United States|Phase III Clinical Research, Fall River, Massachusetts, United States|Michigan Arthritis Research Center, Brighton, Michigan, United States|Westroad Medical Group, Omaha, Nebraska, United States|NC Arthritis & Allergy Care Center, Raleigh, North Carolina, United States|Clinical Research Division, Mayfield Village, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|East Penn Rheumatology Associates, Bethlehem, Pennsylvania, United States|Altoona Ctr. for Clinical Research, Duncansville, Pennsylvania, United States|Clinical Research Center of Reading LLP, West Reading, Pennsylvania, United States|Low Country Rheumatology, Charleston, South Carolina, United States|Arthritis Clinic, Jackson, Tennessee, United States|SCRI, Memphis, Tennessee, United States|Austin Rheumatology Research, Austin, Texas, United States|Research Across America, El Paso, Texas, United States|Center for Arth. & Rheum. Disease, PC, Chesapeake, Virginia, United States|Clinica para el Diagnostico y Tratamiento de las Enfermedades Reumaticas, S.C., Ciudad Mexico, DF, Mexico|Arke Estudios Clinicos, S.A. de C.V., Ciudad Mexico, DF, Mexico|Hospital General de Mexico, Ciudad Mexico, DF, Mexico|Hospital Regional ""1° de Octubre"", ISSSTE, Ciudad Mexico, DF, Mexico|Centro Médico DALINDE, Mexico, Distrito Federal, Mexico|Hospital Aranda de la Parra, Leon, GT, Mexico|Hospital Civil de Guadalajara ""Fray Antonio Alcalde"", Guadalajara, JA, Mexico|Hospital Civil de Guadalajara ""Dr. Juan I. Menchaca"", Guadalajara, JA, Mexico|Centro Médico del Instituto de Seguridad Social del Estado de Mexico y Municipios (CMISSEMYM), Metepec, MX, Mexico|Facultad de Medicina y Hospital Universitario ""Dr. Jose E. Gonzalez"" de la Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"", San Luis Potosi, SL, Mexico",,"https://ClinicalTrials.gov/show/NCT00326339"
13,"NCT00665925","Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis","Taski-2","Completed","Has Results","Rheumatoid Arthritis","Drug: Fostamatinib disodium (R935788)|Drug: Placebo","American College of Rheumatology 20 (ACR20) Response at 6 Months|American College of Rheumatology 20 (ACR20) Response at 1 Week|American College of Rheumatology 20 (ACR20) Response at 2 Weeks|American College of Rheumatology 20 (ACR20) Response at 1 Month|American College of Rheumatology 20 (ACR20) Response at 6 Weeks|American College of Rheumatology 20 (ACR20) Response at 2 Months|American College of Rheumatology 20 (ACR20) Response at 3 Months|American College of Rheumatology 20 (ACR20) Response at 4 Months|American College of Rheumatology 20 (ACR20) Response at 5 Months|American College of Rheumatology 50 (ACR50) Response at 1 Week|American College of Rheumatology 50 (ACR50) Response at 2 Weeks|American College of Rheumatology 50 (ACR50) Response at 1 Month|American College of Rheumatology 50 (ACR50) Response at 6 Weeks|American College of Rheumatology 50 (ACR50) Response at 2 Months|American College of Rheumatology 50 (ACR50) Response at 3 Months|American College of Rheumatology 50 (ACR50) Response at 4 Months|American College of Rheumatology 50 (ACR50) Response at 5 Months|American College of Rheumatology 50 (ACR50) Response at 6 Months|American College of Rheumatology 70 (ACR70) Response at 1 Week|American College of Rheumatology 70 (ACR70) Response at 2 Weeks|American College of Rheumatology 70 (ACR70) Response at 1 Month|American College of Rheumatology 70 (ACR70) Response at 6 Weeks|American College of Rheumatology 70 (ACR70) Response at 2 Months|American College of Rheumatology 70 (ACR70) Response at 3 Months|American College of Rheumatology 70 (ACR70) Response at 4 Months|American College of Rheumatology 70 (ACR70) Response at 5 Months|American College of Rheumatology 70 (ACR70) Response at 6 Months|American College of Rheumatology Index of Improvement (ACRn) at 1 Week|American College of Rheumatology Index of Improvement (ACRn) at 2 Weeks|American College of Rheumatology Index of Improvement (ACRn) at 1 Month|American College of Rheumatology Index of Improvement (ACRn) at 6 Weeks|American College of Rheumatology Index of Improvement (ACRn) at 2 Months|American College of Rheumatology Index of Improvement (ACRn) at 3 Months|American College of Rheumatology Index of Improvement (ACRn) at 4 Months|American College of Rheumatology Index of Improvement (ACRn) at 5 Months|American College of Rheumatology Index of Improvement (ACRn) at 6 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 1 Month|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 2 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 3 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 4 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 5 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 6 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 1 Month|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 2 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 3 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 4 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 5 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 6 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 1 Month|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 2 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 3 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 4 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 5 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 6 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 1 Month|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 2 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 3 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 4 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 5 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 6 Months|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at 6 Months|Short Form Health Survey (SF-36) Physical Component Summary (PCS) at 6 Months|Short Form Health Survey (SF-36) Mental Component Summary (MCS) at 6 Months|Alanine Aminotransferase (ALT) >1.5x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >1.5-2x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >2-3x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >3x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >3-5x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >5-10x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >10x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >1.5x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >1.5-2x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >2-3x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >3x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >3-5x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >5-10 x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >10 x Upper Limit of Normal (ULN)|Alkaline Phosphatase >1.5 x Upper Limit of Normal (ULN) and >1.5 Times Baseline|Bilirubin >1.5 x Upper Limit of Normal (ULN)|Bilirubin >2 x Upper Limit of Normal (ULN)|Absolute Neutrophil Count (ANC) <1500/mm3","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","457","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-010","May 2008","June 2009","June 2009","April 24, 2008","June 13, 2016","September 16, 2016","Divison of Rheumatology Allergy and Immunology, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|Arthritis & Osteoporosis Center, PC, Hamden, Connecticut, United States|Cynthia Morgan, Washington, District of Columbia, United States|Florida Medical Research Institute, Gainsville, Florida, United States|Paddock Park Clinical Research, Ocala, Florida, United States|Jeffrey Poiley, MD, Orlando, Florida, United States|Lovelace Scientific Resources, Sarasota, Florida, United States|Rheumatology Associates, SC, Chicago, Illinois, United States|Memorial Medical Group Clinical Research Inst, South Bend, Indiana, United States|Center for Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States|The Osteoporosis & Clinical Trials Center, Hagerstown, Maryland, United States|Fiechtner Research, Inc., Lansing, Michigan, United States|Westroads Medical Group, Omaha, Nebraska, United States|North Carolina Arthritis & Allergy Care Center, Raleigh, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Health Research of Oklahoma, Oklahoma, Oklahoma, United States|Rheumatology Associates, Erie, Pennsylvania, United States|Clinical Research Center of Reading, LLP, West Reading, Pennsylvania, United States|Rheumatic Disease Associates, Willow Grove, Pennsylvania, United States|Rheumatology Associates, Charleston, South Carolina, United States|Austin Rheumatology & Research, Austin, Texas, United States|Arthritis Center of South Texas, San Antonio, Texas, United States|Arthritis Northwest, PLLC, Spokane, Washington, United States|MNTranspH ""Tsar Boris Treti"", Sofia, Gsof, Bulgaria|MHAT ""Kaspela"", Plovdiv, PLO, Bulgaria|MHAT Ruse, Ruse, Bulgaria|DCC ""Sv. Anna"" Sofia, Sofia, Bulgaria|Unidad Medica Torre Plaza, Medellín, Antioquia, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Atlántico, Colombia|Reumatologos del Caribe, Barranquilla, Atlántico, Colombia|CIREEM, Bogota, Cundinamarca, Colombia|Fundación Instituto de Reumatología, Bogota, Cundinamarca, Colombia|Riesgo de Fractura S.A, Bogota, Cundinamarca, Colombia|Private Office, Bogotá, Cundinamarca, Colombia|Centro Medico Carlos Ardila Lulle, Bucaramanga, Santander, Colombia|SERVIMED, Bucaramanga, Santander, Colombia|Arké Estudios Clínicos S.A de C.V, Mexico, D.f., Mexico|Clínica para el Diagnostico y Tratamiento de, Mexico, D.f., Mexico|Hospital Ángeles Metropolitano, Mexico, D.f., Mexico|Hospital General de México, Mexico, D.f., Mexico|Centro Médico DALINDE, Mexico, Distrito Federal, Mexico|Hospital Aranda de la Parra, Leon, Guanajuato, Mexico|Instituto Jalisciense de Investigación Clínica, Guadalajara, Jalisco, Mexico|Hospital Civil de Guadalajara ""Fray Antonio A, Guadalajara, Jalisco, Mexico|Centro de Investigacion Clinical de Morelia, Morelia, Michoacan, Mexico|Hospital Inovamed , Torre Médica, Cuernavaca, Morelos, Mexico|Christus Muguerza del Parque, Chihuahua, Mexico|NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland|Szpit. Spec.Nr 1, Odz. Reumatol. i Reh., Bytom, Poland|Wojewodzki Szpital Zespolony Oddzial Reumatol, Elblag, Poland|Mazowieckie Centrum Badan Klinicznych, Grodzisk Mazowiecki, Poland|Malopolskie Centrum Medyczne SC, Krakow, Poland|Krakowskie Centrum Medyczne NZOZ, Krakow, Poland|NZOZ Reumed, Lublin, Poland|NZOZ ""Nasz Lekarz"", Torun, Poland|Synexus SCM, Wroclaw, Poland|ASK Klinika Reumatologii i Chor. Wewn., Wroclaw, Poland|ZOZ w Zyradowie Oddzial Reumatologii, Zyradow, Poland|Spitalul Clinic Judetean de Urgenta Cluj Reum, Cluj-Napoca, Cluj, Romania|Spitalul Clinic ""Sf. Maria"" Med Int si Reumat, Bucuresti, Sector 1, Romania|CMI ""Cristei R. Dorica"", Braila, Romania|Spitalul de Urgenta al MAI Dr. D. Gerota, Bucuresti, Romania|Spitalul Judetean ""Dr. Fogolyan Kristol"", Sf. Gheorghe, Romania|Spitalul Clinic Judetean Sibiu, Sibiu, Romania",,"https://ClinicalTrials.gov/show/NCT00665925"
14,"NCT00665626","Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)","Taski-3","Completed","Has Results","Rheumatoid Arthritis","Drug: Fostamatinib disodium (R935788)|Drug: Placebo","American College of Rheumatology 20 (ACR20) Response at 3 Months|American College of Rheumatology 50 (ACR50) Response at 3 Months|American College of Rheumatology 70 (ACR70) Response at 3 Months|American College of Rheumatology Index of Improvement (ACRn) at 3 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <2.6 at 3 Months|Disease Activity Score-C-Reactive Protein (DAS28-CRP) <3.2 at 3 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <2.6 at 3 Months|Disease Activity Score-Erythrocyte Sedimentation Rate (DAS28-ESR) <3.2 at 3 Months|American College of Rheumatology 20 (ACR20) Response at Week 1|American College of Rheumatology 20 (ACR20) Response at Week 2|Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Erosion Score at 3 Months|Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Osteitis Score at 3 Months|Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) Synovitis Score at 3 Months|Alanine Aminotransferase (ALT) >1.5x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >1.5-2x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >2-3x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >3x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >3-5x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >5-10x Upper Limit of Normal (ULN)|Alanine Aminotransferase (ALT) >10x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >1.5x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >1.5-2x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >2-3x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >3x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >3-5x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >5-10x Upper Limit of Normal (ULN)|Aspartate Aminotransferase (AST) >10x Upper Limit of Normal (ULN)|Alkaline Phosphatase >1.5x Upper Limit of Normal (ULN) and >1.5x Baseline|Bilirubin >1.5x Upper Limit of Normal (ULN)|Bilirubin >2x Upper Limit of Normal (ULN)|Absolute Neutrophil Count (ANC) <1500/mm3","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-011","May 2008","June 2009","June 2009","April 24, 2008","July 15, 2016","May 1, 2017","Arthritis & Rheumatic Disease Specialties, Aventura, California, United States|Desert Medical Advances, Palm Desert, California, United States|San Diego Arthritis & Medical Clinic, San Diego, California, United States|Department of Rheumatology, Washington, District of Columbia, United States|RASF-Clinical Research Center, Boca Raton, Florida, United States|Florida Medical Research Institute, Gainsville, Florida, United States|Paddock Park Clinical Research, Ocala, Florida, United States|Lovelace Scientific Resources, Sarasota, Florida, United States|Intermountain Orthopedics, Boise, Idaho, United States|Rheumatology Associates, SC, Chicago, Illinois, United States|Memorial Medical Group Clinical Research Inst, South Bend, Indiana, United States|Center for Arthritis & Osteoperosis, Elizabethtown, Kentucky, United States|The Osteoporosis & Clinical Trials Center, Cumberland, Maryland, United States|The Osteoporosis & Clinical Trials Center, Hagerstown, Maryland, United States|Fiechtner Research, Inc., Lansing, Michigan, United States|Westroads Medical Group, Omaha, Nebraska, United States|North Shore Long Island Jewich Health System, Lake Success, New York, United States|Andrew Porges, MD PC, Roslyn, New York, United States|Rheumatology Associates of Long Island, Smithtown, New York, United States|Clinical Research Division, Mayfield Village, Ohio, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|Rheumatology Associates, Erie, Pennsylvania, United States|Clinical Research Center of Reading, LLP, West Reading, Pennsylvania, United States|Rheumatic Disease Associates, Willow Grove, Pennsylvania, United States|Austin Rheumatology & Research, Austin, Texas, United States|Houston Institute for Clinical Research, Houston, Texas, United States|Arthritis Northwest, PLLC, Spokane, Washington, United States|ZNA Middelheim, Antwepen, Belgium|UZ Gent, Gent, Belgium|CHU Liege, Liege, Belgium|Reumalab S.A., Medellin, Antioquia, Colombia|Reumatologos del Caribe, Barranquilla, Atlantico, Colombia|CIREEM, Bogota, Cundinamarca, Colombia|Dr. Renato Guzman, Bogota, Cundinamarca, Colombia|Riesgo de Fractura S.A., Bogota, Cundinamarca, Colombia|Hopital Pellegrin, Bordeaux Cedex, France|Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany|Klinikum Eilbek, Hamburg, Germany|ClinPharm International GmbH Leipzig, Leipzig, Germany|Rheumazentrum am Universitatsklinikum Leipzig, Leipzig, Germany|Universitatsklinikum Wurzburg, Wurzburg, Germany|Reumatologia Azienda Ospedaliera Universitaria, Siena, Italy|Azienda Ospedaliera Santa Maria della Miseri, Udine, Italy|Instituto de Ginecologia y Reproduccion, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT00665626"
15,"NCT01900249","To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca","DROPS","Completed","Has Results","Keratoconjunctivitis Sicca","Drug: R348 Ophthalmic Solution, 0.2%|Drug: R348 Ophthalmic Solution, 0.5%|Drug: Placebo","Change of Corneal Fluorescein Staining of the Inferior Cornea Region.","Rigel Pharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-932348-003","July 2013","July 2014","July 2014","July 16, 2013","October 3, 2016","October 3, 2016","Sall Research Medical Center, Artesia, California, United States|North Bay Eye, Petaluma, California, United States|Martel Medical Eye Group, Rancho Cardova, California, United States|Specialty Eye Care, Parker, Colorado, United States|International Research Center, Brandon, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Clayton Eye Center, Morrow, Georgia, United States|Coastal Research Associates, Roswell, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Chicago Cornea Consultants, Hoffman Estates, Illinois, United States|Koffler Vision Group, Lebanon, Kentucky, United States|Taustine Eye Center, Louisville, Kentucky, United States|Comprehensive Eye Care, Ltd/Vision Research Institute, LLC, Washington, Missouri, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|Charlotte Eye Ear Nose and Throat Associates, PA, Charlotte, North Carolina, United States|Cornerstone Eyecare, High Point, North Carolina, United States|Abrams Eye Center, Cleveland, Ohio, United States|Glaucoma Consultants and Center for Eye Research, Mt. Pleasant, South Carolina, United States|Chattanooga Eye Institute, Chattanooga, Tennessee, United States|Eye Clinics of South Texas, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01900249"
16,"NCT03363334","Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP",,"No longer available","No Results Available","Immune Thrombocytopenic Purpura","Drug: Fostamatinib disodium 100 mg|Drug: Fostamatinib disodium 150 mg",,"Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"C-935788-055",,,,"December 6, 2017",,"August 1, 2018",,,"https://ClinicalTrials.gov/show/NCT03363334"
17,"NCT01597050","Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions","SKINDLE","Completed","Has Results","Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic","Drug: R932333|Drug: Placebo","Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions.","Rigel Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-932333-002","August 2012","September 2013","September 2013","May 11, 2012","June 8, 2016","July 14, 2016","Wallace Rheumatic Study Center, Los Angeles, California, United States|Stanford Dermatology, Redwood City, California, United States|Memorial Medical Group Clinical Research Institute, South Bend, Indiana, United States|North Shore Long Island Health System, Lake Success, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|University of Pennsylvania-Dermatology Research Office, Philadelphia, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|University of Texas Medical School at Houston, Houston, Texas, United States|University of Utah Department of Dermatology, Salt Lake City, Utah, United States|Virginia Clinical Research, Inc, Norfolk, Virginia, United States|University of British Columbia, Vancouver Dermatology Clinical Trials Unit, Vancouver, British Columbia, Canada|Dermadvances Research, Winnipeg, Manitoba, Canada|Lynderm Research, Inc, Markham, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01597050"
18,"NCT01591044","A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma","SITAR","Completed","Has Results","Asthma","Drug: Placebo|Drug: R940343 1mg|Drug: R940343 2mg","Change in FEV1","Rigel Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","301","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-940343-004","July 2012","July 2013","July 2013","May 3, 2012","September 29, 2016","September 29, 2016","California Research Medical Group, Inc, Fullerton, California, United States|Allergy Medical Clinic Research Division, Los Angeles, California, United States|California Allergy & Asthma Medical Group, INC, Los Angeles, California, United States|Southern California Institute for Respiratory Diseases, Inc., Los Angeles, California, United States|Allergy & Asthma Associates of Southern California, Mission Viejo, California, United States|CHOC PSF, AMC, Division of Allergy, Asthma & Immunology, Orange, California, United States|Peninsula Research Associates, Rolling Hills Estates, California, United States|Allergy Associates Medical Group. Inc., San Diego, California, United States|Allergy & Asthma Med Group/Research Center, San Diego, California, United States|Allergy & Asthma Associates of Santa Clara Valley, San Jose, California, United States|Bensch Research Associates, Stockton, California, United States|Colorado Allergy and Asthma Clinic, PC, Centennial, Colorado, United States|Asthma & Allergy Associates, PC, Colorado Springs, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Colorado Allergy & Asthma Centers, PC, Denver, Colorado, United States|Florida Center for Allergy & Asthma Research, Aventura, Florida, United States|Accelovance, Melbourne, Florida, United States|Sarasota Clinical Research, Sarasota, Florida, United States|Georgia Pollens Clinical Research Centers, Inc., Albany, Georgia, United States|Idaho Allergy DBA Idaho Research, Eagle, Idaho, United States|Sneeze, Wheeze & Itch Associates, Normal, Illinois, United States|Chesapeake Clinical Research, Inc., Baltimore, Maryland, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Respiratory Medicine Researh Institute of Michigan, Ypsilanti, Michigan, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Clinical Research Institute, Inc., Plymouth, Minnesota, United States|Clinical Research of The Ozarks, Inc., Columbia, Missouri, United States|The Clinical Research Center, LLC, St Louis, Missouri, United States|Clinical Research Group of Montana PLLC, Bozeman, Montana, United States|The Asthma & Allergy Center, Bellevue, Nebraska, United States|Atlantic Research Center, LLC, Ocean, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Allergy Consultants, PA, Verona, New Jersey, United States|New York Pulmonary Associates, P.C., New York, New York, United States|Allergy Asthma Immunology of Rochester (AAIR), Rochester, New York, United States|Peters Medical Research, High Point, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|Allergy & Asthma Research Group, Eugene, Oregon, United States|Clinical Research Inst. of Southern Oregon, PC, Medford, Oregon, United States|Allergy Associates Research Center, Portland, Oregon, United States|Allergy & Clinical Immunology Associates, Pittsburgh, Pennsylvania, United States|National Allergy, Asthma and Uticaria Center of Charleston, Charleston, South Carolina, United States|Pharmaceutical Research & Consulting, Inc., Dallas, Texas, United States|Western Sky Medical Research, Inc., El Paso, Texas, United States|Live Oak Allergy & Asthma Clinic, Live Oak, Texas, United States|Allergy & Asthma Care of Waco, PA, Waco, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States|ASTHMA, Inc., Seattle, Washington, United States|MultiCare Pulmonary Specialists, Tacoma, Washington, United States|Joseph Greenbaum, MD, Hamilton, Ontario, Canada|Cheema Research, Inc., Missassauga, Ontario, Canada|Niagara Clinical Research, Niagara Falls, Ontario, Canada|Ottawa Allergy Research Corp, Ottawa, Ontario, Canada|Pulmonary Care Clinic, Toronto, Ontario, Canada|Primary Care Lung Clinic, Toronto, Ontario, Canada|Dynamik Research, Inc., Pointe-Claire, Quebec, Canada|Centre De recherche Appliquee en Allergie DeQuebec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01591044"
19,"NCT00752999","Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus","SOLEIL","Withdrawn","No Results Available","Systemic Lupus Erythematosus","Drug: Fostamatinib Disodium (R935788)|Drug: Placebo","The primary efficacy endpoint is defined as the decrease from baseline in the SELENA-SLEDAI score at 6 months.|Composite Responder analysis defined as ≥4 points improvement in SELENA-SLEDAI and no 'Severe SLE flare' after Week 6. No worsening (≤10 mm on VAS) of Physician Global Assessment, or, no worsening of SF 36 PCS (not >-0.8) or PFI (not >2.5)|Attainment of daily prednisone dose decrease in those patients on daily corticosteroids by 50% or to ≤ 7.5 mg prednisone (or equivalent for other corticosteroids) at 3 and 6 months.|Decrease from baseline in SELENA-SLEDAI score at each post baseline visit.|Attainment of improvement in SELENA-SLEDAI by ≥ 2 points at Weeks 2 and 4.|Attainment of improvement in SELENA-SLEDAI by ≥ 4 points at each post baseline visit.|Change from baseline of Physician Global Assessment by VAS over 6 months.|Time to rescue medication.|Time to severe SLE flare by SELENA Flare Index.|Change from baseline in the component scores of the SF 36 at Month 3 and Month 6.|Effects on liver function tests, clinically significant reductions in peripheral neutrophil counts, G-I adverse effects, new onset or aggravated hypertension, and other adverse effects as they may appear.","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-015|2008-004472-50","November 2008","November 2009","March 2010","September 16, 2008",,"April 30, 2012",,,"https://ClinicalTrials.gov/show/NCT00752999"
20,"NCT00115089","7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis",,"Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: R926112|Drug: Beclomethasone dipropionate","Change in total nasal symptom score from baseline over time|Change in individual symptoms|Global therapeutic response|Quality of life score","Rigel Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","C-926112-005A","July 2005",,"September 2005","June 21, 2005",,"November 11, 2005",,,"https://ClinicalTrials.gov/show/NCT00115089"
21,"NCT04543279","Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia",,"Recruiting","No Results Available","Myelofibrosis","Drug: Fostamatinib|Drug: Ruxolitinib","Platelet response (Part A)|Toxicity of fostamatinib and ruxolitinib treatment (Part B)|Number of participants eligible to initiate therapy with ruxolitinib (Part A)|Toxicity of fostamatinib treatment (Part A)|Number of participants who permanently discontinue fostamatinib due to fostamatinib related adverse events(Part A)|Number of participants who require treatment interruption of fostamatinib due to adverse events (Part A)|Number of participants who was dose escalated and tolerated fostamatinib dose greater than 100 mg BID (Part A)|Number of participants who achieve 35% or greater reduction in spleen volume as determined by ultrasound at week 12 of fostamatinib treatment (Part A)|Mean reduction is spleen volume as determined by ultrasound at week 12 of fostamatinib treatment (Part A)|Number of participants with 50% or greater improvement in Total Symptom Score (Part A)|Number of participants who achieve platelet transfusion independence (Part A)|Number of participants with anemia who achieve RBC transfusion independence (Part A)|Change in marrow fibrosis by WHO grading (Part A)|Number of participants with 35% or greater reduction in spleen volume as determined by ultrasound after 12 weeks of combination treatment (Part B)|Mean reduction in spleen volume as determined by ultrasound after 12 weeks of combination treatment (Part B)|Number of participants with 50% or greater improvement in Total Symptom Score (Part B)|Duration of uninterrupted ruxolitinib treatment (Part B)|Change in marrow fibrosis by WHO grading (Part B)","Washington University School of Medicine|Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202011080","May 3, 2021","May 31, 2024","May 31, 2024","September 10, 2020",,"May 6, 2021","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04543279"
22,"NCT04904276","Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy",,"Recruiting","No Results Available","ITP|Immune Thrombocytopenia","Drug: Fostamatinib","Fostamatinib dosing|Platelet counts over time during the course of fostamatinib therapy|Use of concomitant medications related to ITP|Use of ITP Rescue Medication|Safety of fostamatinib|ITP-PAQ Quality of life measure|Treatment satisfaction measure (MSQ)|SF-36 Quality of life measure","Rigel Pharmaceuticals","All","18 Years to 100 Years   (Adult, Older Adult)",,"45","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","O-FOSTA-901","May 18, 2021","December 2022","December 2022","May 27, 2021",,"July 19, 2021","Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois, United States|Maryland Oncology Hematology, P.A, Clinton, Maryland, United States|Maryland Oncology Hematology, P.A, Columbia, Maryland, United States|Maryland Oncology Hematology, P.A, Rockville, Maryland, United States|Maryland Oncology Hematology, P.A, Silver Spring, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Regional Cancer Care Associates, LLC, Little Silver, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04904276"
23,"NCT04629703","Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",,"Recruiting","No Results Available","Covid19|SARS (Severe Acute Respiratory Syndrome)|SARS Pneumonia|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere|Pneumonia|Pneumonia, Viral","Drug: Fostamatinib|Drug: Placebo","Progression to severe/critical disease within 29 days of first dose of study treatment|Proportion of subjects transferred into the intensive care unit (ICU) or who died by Day 29","Rigel Pharmaceuticals","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","308","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C-935788-061","February 22, 2021","April 2022","May 2022","November 16, 2020",,"November 30, 2021","University of California Irvine, Orange, California, United States|Alternative Research Associates, LLC, Hialeah, Florida, United States|Alternative Research Associates, LLC, Miami, Florida, United States|Loyola University Medical School, Maywood, Illinois, United States|Harvard Medical School- Bringham and Women's Hospital, Boston, Massachusetts, United States|Ascension Medical Group- St. John Clinic Infectious Disease, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Houston Methodist Research Institute, Houston, Texas, United States|Clinica Chutro, Cordoba, CP, Argentina|Hospital Lencinas, Godoy Cruz, Mendoza, Argentina|Corporacion Medica de General San Martin, San Martin, Provincia De Buenos Aires, Argentina|Hospital de Alta Complejidad Cuenta Alta, Buenos Aires, Argentina|Hospital Del Bicentenario - Dr. Luis Federico Leloir, Buenos Aires, Argentina|Clinica Zabala, Buenos Aires, Argentina|Clinica Adventista Belgrano, Buenos Aires, Argentina|Clinica Monte Grande, Buenos Aires, Argentina|Hospital de Infecciosas Dr.Francisco Javier Muñiz, Buenos Aires, Argentina|Sanatorio Guemes, Buenos Aires, Argentina|Sanatorio Sagrado Corazon, Buenos Aires, Argentina|Hospital San Roque, Córdoba, Argentina|Sanatorio Mayo Privado, Córdoba, Argentina|Hospital das Clínicas da Universidade Federal de Goiás (HC/UFG), Goiânia, Goiás, Brazil|Hospital Luxenburgo-Associação Mário Penna, Belo Horizonte, Minas Gerais, Brazil|Hospital Universitario de Maringa, Maringá, Parana, Brazil|Hosp. Angelina Caron, Campina Grande do Sul, Paraná, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre - ISCMPA, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital des clinicas de porto alegre - Centro de pequisas clinicas, Porto Alegre,, RS, Brazil|Complexo de Prevenção, Diagnóstico, Terapia e Reabilitação Respiratória LTDA, Blumenau, Santa Catarina, Brazil|Hospital Alemão Oswaldo Cruz (HAOC), Bela Vista, Sao Paolo, Brazil|Pontificia Universidade Catolica de Campinas (PUC-CAMP) - Hospital e Maternidade Celso Pierro (HMCP), Campinas, Sao Paolo, Brazil|Hospital Bandeirantes (LeForte), Liberdade, Sao Paolo, Brazil|Hospital Universitário São Francisco na Providência de Deus, Braganca Paulista, Sao Paulo, Brazil|Clinica de Alergia Martti Antila S/S Ltda, Sorocaba, Sao Paulo, Brazil|Fundação Faculdade Reg. de Med de SJRP, São José Do Rio Preto, Sao Paulo, Brazil|Star Medica Vivo Bicentenario, Nezahualcóyotl, Mex, Mexico|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo Leon, Mexico|Köhler & Milstein Research, Mérida, Yucatán, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Nuevo Hospital Civil de Guadalajara, Guadalajara, Mexico|Centro Medico Issemym Toluca, Metepec, Mexico|The American British Cowdray Medical Center I.A.P., Mexico City, Mexico|Hospital Ángeles Roma, Mexico, Mexico|CEPREP Centro de Prevención y Rehabilitación de Enfermedades Pulmonares Crónicas, Nuevo León, Mexico|Hospital Civil de Culiacan, Sinaloa, Mexico|Hospital Civil de Culiacan, Sinaloa, Mexico|Hospital Militar Central, Jesús María, Lima, Peru|EsSalud - Hospital Nacional Alberto Sabogal Sologuren, Lima, Peru|Hospital de Chancay, Lima, Peru|Hospital Maria Auxiliadora, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Hospital Nacional Hipolito Unanue, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT04629703"
24,"NCT04138927","A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",,"Enrolling by invitation","No Results Available","Warm Antibody Autoimmune Hemolytic Anemia","Drug: Fostamatinib disodium","Adverse Events|Blood Pressure|Absolute Neutrophil Count (ANC)|Achievement of Durable Hemoglobin Response|Total Duration of Response|Corticosteroid dose","Rigel Pharmaceuticals","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","90","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-935788-058","October 30, 2019","February 2024","February 2024","October 25, 2019",,"July 23, 2021","University of Southern California, Los Angeles, California, United States|Harbor UCLA - Lundquist Institute, Torrance, California, United States|John Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|University of Washington, Seattle, Washington, United States|Cancer Trials Unit, Brisbane, Queensland, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Hanusch-Krankenhaus, Vienna, Austria|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|AZ Nikolaas, Sint-Niklaas, Belgium|""University Multiprofile Hospital for Active Treatment ""Sveti Georgi"" EAD, Plovdiv, Clinic of Medical oncology, Plovdiv, Bulgaria|""University Multiprofile Hospital for Active Treatment ""Sveta Marina"""" EAD, Varna, Clinic of Clinical Haematology, Varna, Bulgaria|Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika, Brno, Czechia|Fakultni nemocnice Ostrava Klinika hematoonkologie, Ostrava, Czechia|CHU de Bordeaux - GH Sud- Hôpital Haut Lévêque Service Médecine Interne et Maladies Infectieuses, Pessac, France|LTD Multiprofile Clinic Consilium Medulla, Tbilisi, Georgia|M. Zodelava Hematology Centre, Tbilisi, Tbilisi, Georgia|Universitätsklinikum Essen, Essen, Germany|Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico di Milano - UO Ematologia, Milano, Italy|Academic Medical Center Amsterdam, Amsterdam, Netherlands|Haukeland University Hospital, Bergen, Norway|National Research Center for Hematology, Moscow, Russian Federation|State Budgetary Healthcare Institution Oncology Dispensary No. 2 of the Ministry of Health of the Krasnodar Territory, Sochi, Russian Federation|Clinical Centre of Vojvodina, Clinic for Hematology, Novi Sad, Serbia|Hospital Clinic de Barcelona, Barcelona, Spain|City Clinical Hospital № 4, Hematology Center, Dnipro, Ukraine|Kyiv City Clinical Hospital №9, hematology department №1, Kyiv, Ukraine|Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04138927"
25,"NCT03764618","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA",,"Active, not recruiting","No Results Available","Warm Antibody Autoimmune Hemolytic Anemia","Drug: Fostamatinib disodium|Drug: Placebo","Durable Hemoglobin Response|Subjects with a hemoglobin response by Week 24|Frequency of rescue AIHA regimens used|Hemoglobin assessments exhibiting a hemoglobin response","Rigel Pharmaceuticals","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-935788-057","April 24, 2019","April 2022","April 2022","December 5, 2018",,"November 26, 2021","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Arizona Oncology Associates, PC--HOPE Division, Tucson, Arizona, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|Harbor UCLA - Lundquist Institute, Torrance, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley, Colorado, United States|Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Affiliated Oncologists, Chicago Ridge, Illinois, United States|John Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Rutgers - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Duke Cancer Network, Clayton, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Oncology - Baylor Research Institute, Dallas, Texas, United States|Clear Lake Specialties, Research Dept., Webster, Texas, United States|American Oncology Network Vista Oncology Division, Olympia, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Versiti Wisconsin, Inc., Milwaukee, Wisconsin, United States|Marshfield Clinic Cancer Center - Stevens Point, Stevens Point, Wisconsin, United States|Concord Repatriation General Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital - Cancer Trials Unit, Brisbane, Queensland, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Universitätsklinik Innsbruck - Innere Medizin V, Innsbruck, Austria|Universitätsklinikum Salzburg, 3.Medizin/Onkologie, Salzburg, Austria|Hanusch-Krankenhaus, Vienna, Austria|Medizinsche Universität Wien, Wien, Austria|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Ziekenhuis Network Antwerp, Stuivenberg, Antwerpen, Belgium|Universitair Ziekenhuis Antwerpen - Hematologie, Edegem, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|""University Multiprofile Hospital for Active Treatment - Dr Georgi Stranski"" EAD, Pleven, Clinic of Clinical Haematology, Pleven, Bulgaria|""University Multiprofile Hospital for Active Treatment ""Sv. Ivan Rilski "" EAD, Clinic of Clinical Hematology, Department of Clinical Hematology, Sofia, Bulgaria|""University Multiprofile Hospital for Active Treatment 'Alexandrovska"" EAD, Clinic of Clinical Haematology, Sofia, Bulgaria|""Specialized Hospital for Active Treatment of Hematological Diseases"" EAD, Sofia, Clinic of Clinical Haematology, Sofia, Bulgaria|""University Multiprofile Hospital for Active Treatment ""Sveta Marina"""" EAD, Varna, Clinic of Clinical Haematology, Varna, Bulgaria|Hamilton Health Sciences- McMaster University Medical Centre, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika, Brno, Czechia|Fakultni nemocnice Ostrava Klinika hematoonkologie, Ostrava, Czechia|Ustav Hematologie a Krevni Transfuze, Praha, Czechia|Aalborg University Hopital, Aalborg, Denmark|Aarhus University Hospital - Dept of Hematology, Aarhus N, Denmark|Herlev and Gentofte Hospital, Herlev, Denmark|CHU Angers, Angers, France|Institut d'hématologie de Basse Normandie, CHU Caen, Caen, France|CHU Estaing - Chirurgie digestive et Médecine interne, Clermont-Ferrand, France|CHU Henri Mondor, Créteil, France|Hôpital Saint Antoine, Paris, France|CHU de Bordeaux - GH Sud- Hôpital Haut Lévêque Service Médecine Interne et Maladies Infectieuses, Pessac, France|CHU Toulouse, IUCT Oncopôle, Toulouse, France|M. Zodelava Hematology Centre, Tbilisi, Tbilisi, Georgia|LTD Multiprofile Clinic Consilium Medulla, Tbilisi, Georgia|Universitätsklinikum Essen, Essen, Germany|University of Leipzig Medical Center, Medical Department I - Haematology and Cell Therapy, Medical Oncology, Hemophilia, Leipzig, Germany|Semmelweis Egyetem, Általános Orvostudományi Kar, I.sz. Belgyógyászati Klinika, Haematológiai Osztály,, Budapest, Hungary|Szabolcs-Szatmár- Bereg Megyei Kórházak és Egyetemi Oktatókórház, Jósa András Oktatókórház, Nyíregyháza, Hungary|Pécsi Tudományegyetem, Klinikai Központ, I.számú Belgyógyászati Klinikai, Hematológiai Tanszék, Pécs, Hungary|ASST degli Spedali Civili di Brescia, Ematologia UOC, Brescia, Italy|Fondazione IRCCS Ca'Granda - Ospedale Maggiore Policlinico di Milano - UO Ematologia, Milano, Italy|SCDU Ematologia AOU ""Maggiore della Carità"", Novara, Italy|Ospedale Maggiore, SC Ematologia - Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy|ULSS8 Berica Ospedale San Bortolo - Unità Operativa Complessa di Ematologia, Vicenza, Italy|Academisch Medisch Centrum, Amsterdam, Netherlands|Haukeland University Hospital, Bergen, Norway|Østfold Hopital, Grålum, Norway|Ålesund Hospital, Ålesund, Norway|Coltea Clinical Hospital, Bucharest, Romania|Emergency University Hospital Bucharest, Bucharest, Romania|""Prof. Dr. Ion Chiricuta"" Institute of Oncology Cluj-Napoca, Cluj-Napoca, Romania|National Research Center for Hematology, Moscow, Russian Federation|Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|State Budgetary Healthcare Institution of Moscow city ""City Clinical Hospital No 40 Department of Healthcare of Moscow city"", Moscow, Russian Federation|State Budgetary Healthcare Institution of Novosibirsk Region ""City Clinical Hospital №2"", Novosibirsk, Russian Federation|State Budgetary Healthcare Institution Oncology Dispensary No. 2 of the Ministry of Health of the Krasnodar Territory, Sochi, Russian Federation|Regional State Autonomous Healthcare Institution ""Tomsk Regional Clinical Hospital"", Tomsk, Russian Federation|University Hospital Medical Center ""Bezanijska Kosa"", Department of Hematology, Belgrade, Serbia|Clinical Center Nis, Clinic for Hematology, Niš, Serbia|Clinical Centre of Vojvodina, Clinic for Hematology, Novi Sad, Serbia|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario y Politecnico La Fe - Servicio de Hematología, Valencia, Spain|Cherkasy Regional Oncology Dispensary, Hematology Center, Cherkasy, Ukraine|City Clinical Hospital № 4, Hematology Center, Dnipro, Ukraine|Kyiv City Clinical Hospital №9, hematology department №1, Kyiv, Ukraine|East Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom|Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom|Hammersmith Hospital, London, United Kingdom|The Royal London Hospital, Bart's Health NHS Trust, London, United Kingdom|Sandwell and West Birmingham NHS Trust, West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03764618"
26,"NCT01733992","A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease",,"Completed","No Results Available","Keratoconjunctivitis Sicca","Drug: R348 Ophthalmic Solution, 0.2%|Drug: R348 Ophthalmic Solution, 0.5%|Drug: R348 Ophthalmic Solution, 1.0%|Drug: Placebo","Change in corneal fluorescein staining|Change in conjunctival lissamine green staining","Rigel Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C-932348-002","November 2012","February 2013","February 2013","November 27, 2012",,"August 4, 2014","Andover Eye Associates, Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01733992"
27,"NCT00798096","Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma",,"Completed","Has Results","T Cell Lymphoma","Drug: Fostamatinib Disodium","The Primary Efficacy Endpoint for This Study is Overall Regressive Response Rate (ORRR): Proportion of Patients With a Best Response of Complete Response (CR), Partial Response (PR), or Regressive Stable Disease (RSD).|Clinical Benefit Rate is the Proportion of Patients With Best Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD).|Overall Response Rate (ORR) is the Proportion of Patients With a Best Response of Complete Response (CR) or Partial Response (PR).|Duration of Overall Response is the Time From First Documentation of Complete or Partial Response, Whichever Occurs Earlier, to Discontinuation of Study Drug.","Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4300C00024|C-935788-017","March 2009","April 2010","April 2010","November 25, 2008","June 12, 2014","September 19, 2016","Research Site, San Francisco, California, United States|Research Site, Stanford, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, Omaha, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00798096"
28,"NCT00706342","Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)",,"Completed","Has Results","Purpura, Thrombocytopenic, Idiopathic","Drug: Fostamatinib Disodium / R935788","Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 2|Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 6|Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 12|Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 24|Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Month 12|Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Month 24","Rigel Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4300C00022|C-935788-007","January 2007","April 2010","April 2010","June 27, 2008","August 13, 2014","June 3, 2016","Research Site, New York, New York, United States|Research Site, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00706342"
29,"NCT00446095","Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma",,"Completed","Has Results","Lymphoma","Drug: fostamatinib","Overall Response Rate as Assessed According to the""Revised Response Criteria for Malignant Lymphoma"" (Cheson 2007).|Clinical Benefit Rate as Assessed According to the ""Revised Response Criteria for Malignant Lymphoma"" (Cheson 2007).|Progression Free Survival (PFS)|Overall Survival (OS)","Rigel Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","81","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4300C00023|C-935788-009","April 2007","April 2010","October 2010","March 12, 2007","December 18, 2014","September 19, 2016","Research Site, Los Angeles, California, United States|Research Site, Stanford, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, Omaha, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00446095"
30,"NCT05040698","Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa",,"Not yet recruiting","No Results Available","Hidradenitis Suppurativa","Drug: Fostamatinib","Week 4 evaluation|Week 12 evaluation|Grade 2/3 Adverse Events|Abscess and Nodule Count Week 4|International Hidradenitis Suppurativa Severity Score (IHS4) Week 4|Abscess and Nodule count week 12|International Hidradenitis Suppurativa Severity Score (IHS4) Week 12|Physician Rated Overall Disease Severity|Dermatology Life Quality Index (DLQI)","Holdsworth House Medical Practice|Rigel Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JFR-001","October 2021","October 2021","October 2022","September 10, 2021",,"September 10, 2021","Holdsworth House Medical Practice, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT05040698"
31,"NCT03246074","Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer",,"Recruiting","No Results Available","Ovarian Cancer","Drug: Fostamatinib and Paclitaxel","Incidence of Treatment-Emergent Adverse Events|Response rate of treatment with combination therapy|Survival determination based on progression-free survival|Drug metabolism determination","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Rigel Pharmaceuticals|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","Female","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1708|IRB00110406","April 3, 2018","October 1, 2022","October 1, 2023","August 11, 2017",,"October 27, 2021","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03246074"
32,"NCT04581954","Inflammatory Signal Inhibitors for COVID-19 (MATIS)","MATIS","Recruiting","No Results Available","Coronavirus|Covid19|Pneumonia","Drug: Ruxolitinib|Drug: Fostamatinib|Other: Standard of care","All-cause mortality|Number and proportion of patients requiring invasive ventilation|Number and proportion of patients requiring non-invasive ventilation (CPAP and high flow nasal oxygen)|Number and proportion of patients requiring invasive ventilation or extracorporeal membrane oxygenation (ECMO)|Number and proportion of patients requiring non-invasive ventilation including continuous positive airway pressure (CPAP) or high flow nasal oxygen|Number and proportion of patients requiring renal replacement therapy|Number and proportion of patients experiencing venous thromboembolism events|Length of stay|Number and proportion of serious adverse events and discontinuations|Absolute change in pneumonia severity on the modified WHO COVID-19 Ordinal Scale","Imperial College London|Imperial College Healthcare NHS Trust|Rigel Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","456","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20HH5926|2020-001750-22","October 2, 2020","December 1, 2021","December 1, 2021","October 9, 2020",,"September 2, 2021","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04581954"
33,"NCT00724945","Comparison of Two Soft Bifocal Contact Lenses",,"Completed","Has Results","Presbyopia","Device: balafilcon A|Device: senofilcon A","Distance Visual Acuity|Near Visual Acuity|Subject Vision","Johnson & Johnson Vision Care, Inc.","All","35 Years to 70 Years   (Adult, Older Adult)","Not Applicable","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-1485CK","July 2008","August 2008","August 2008","July 30, 2008","January 27, 2010","May 21, 2015","Dr. James Weber & Associates, Jacksonville, Florida, United States|Ted Brink & Associates, Jacksonville, Florida, United States|Jacksonville, Florida, United States|Eye Associates of Winter Park, Winter Park, Florida, United States|Lee Rigel, East Lansing, Michigan, United States|Timothy R. Poling, OD, Roanoke, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00724945"
34,"NCT01354223","Clinical Evaluation of Stenfilcon A Soft Contact Lens When Compared to Ocufilcon B Soft Contact Lens",,"Completed","Has Results","Myopia","Device: stenfilcon A contact lens|Device: ocufilcon B contact lens","Objective Assessment: Ocular Response - Biomicroscopy|Comparison of Objective Findings - Number of Adverse Events in Unique Eyes|Comparison of Objective Findings for Contact Lens Visual Acuities - Snellen 20/25 VA or Better|Subjective Assessment of Contact Lens Comfort - No Symptoms of Discomfort|Evaluation of Average Lens Wearing Time - Average Daily Hours Worn","Coopervision, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FC100239","October 2010","March 2011","April 2011","May 16, 2011","March 21, 2014","July 29, 2020","Eric M. White, OD, Inc., San Diego, California, United States|Vision Care Associates, East Lansing, Michigan, United States|Western Reserve Vision Care, Beachwood, Ohio, United States|Primary Eyecare Group, P.C., Brentwood, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01354223"
35,"NCT00241280","Study Intended to Evaluate the Safety and Effectiveness of a Johnson & Johnson Vision Care Inc, (JJVCI) Contact Lens for Use on an Extended-wear Basis for up to 7 Days (6 Nights).",,"Completed","Has Results","Myopia","Device: etafilcon A|Device: galyfilcon A","Monocular Contact Lens Snellen Visual Acuity Worse Than 20/40|Rate of Contact Lens Related Serious and Significant Events (SSE)","Johnson & Johnson Vision Care, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","504","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","CR-1480","September 2005","October 2006","October 2006","October 18, 2005","February 25, 2016","March 24, 2016","Steven S. Grant, OD, Costa Mesa, California, United States|Cole, Cole, and Krohn, Fresno, California, United States|Fukai and Associates, Louisville, Colorado, United States|Peter C. Donshik, MD, Bloomfield, Connecticut, United States|Dr. Ted Brink and Associates, Jacksonville, Florida, United States|Jack J. Yager, OD, Orlando, Florida, United States|Clayton Eye Center, Morrow, Georgia, United States|Eyecare Associates, Bloomington, Illinois, United States|Drs. Hawks, Besler & Rogers, Gardner, Kansas, United States|Lee Rigel, East Lansing, Michigan, United States|Univ Missouri at St. Louis, College of Optometry, St. Louis, Missouri, United States|InSight Eyecare, Warrensburg, Missouri, United States|Drs. Quinn, Quinn and Associates, Athens, Ohio, United States|Central Ohio Eyecare, Columbus, Ohio, United States|Kenji Hamada, OD, Grants Pass, Oregon, United States|West Hills Vision Center, Moon Township, Pennsylvania, United States|Kenneth A. Young, OD, Brentwood, Tennessee, United States|Gary W. Jerkins, MD, Nashville, Tennessee, United States|Premier Vision, Amarillo, Texas, United States|Charles Wegman, OD, Carrollton, Texas, United States|Wishnow-Sugar Vision Group, Katy, Texas, United States|First Eye Care Plano, Plano, Texas, United States|Dr. William Bogus, Salt Lake City, Utah, United States|Scott Jens, OD, Middleton, Wisconsin, United States|Snowy Range Vision Center, Laramie, Wyoming, United States",,"https://ClinicalTrials.gov/show/NCT00241280"
